# SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

> **NCT01362790** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Mesothelioma
- Adenocarcinoma of Lung
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Pentostatin
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** SS1(dsFv)PE38 - lot 073I0809
- **BIOLOGICAL:** SS1(dsFv)PE38 - lot FIL129J01

## Key facts

- **NCT ID:** NCT01362790
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-11
- **Primary completion:** 2016-08-03
- **Final completion:** 2017-08-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362790, "SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01362790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*